Mycenax Biotech Inc. (4726) outlined its operational achievements and mid-to-long-term strategies at its investor conference on Dec. 29. Chairman Pei-Jiun Chen described 2025 as a "Year of Global Realization" for the company. Key milestones include qualifying as a supplier for two internationally marketed biologics and deepening its strategic footprint in Japan. Responding to the global trend of supply chain localization, Mycenax has partnered with Alfresa and other leading Japanese corporations to establish Alfenax. This joint venture will construct a biologics manufacturing base in Japan, focusing on CMO services and distribution. Concurrently, Mycenax is leveraging its expertise in traditional biologics to accelerate its capabilities in emerging biologics, specifically Antibody-Drug Conjugates (ADCs).

Following successful inspections by multiple international regulatory authorities, Mycenax’s GMP Plant 1 has officially entered the commercial manufacturing phase for marketed biologics. This marks a pivotal transformation for Mycenax, evolving from a clinical-stage CDMO into a commercial supplier for global biologics. The stable production of these commercialized products is projected to generate significant recurring revenue starting in late 2025, providing greater operational stability and visibility.

Mycenax continues to strengthen its Japan strategy, building on years of market cultivation. In response to geopolitical shifts and the Japanese government’s initiatives to promote biosimilars, Alfenax has secured substantial support from Japan’s Ministry of Health, Labour and Welfare (MHLW), with subsidies expected to cover up to half of the construction costs. The upcoming Alfenax facility in Akita will serve as an extension of Mycenax’s capacity. While the Akita plant focuses on manufacturing (CMO), the upstream process development needs will be channeled back to Mycenax in Taiwan, creating a synergistic revenue model that boosts overall project momentum.

In the realm of new biologics, Mycenax has actively expanded its ADC capabilities since 2021. In 2025, Mycenax secured exclusive rights to the VLK linker technology from Japan’s RIN Institute. By integrating this with its proprietary multi-arm linker technology, Mycenax is establishing a competitive, next-generation one-stop ADC service platform.

Chairman Pei-Jiun Chen emphasized that Mycenax will focus on core manufacturing capabilities that meet the rigorous standards of internationally marketed biologics, thereby building stable and predictable revenue streams. With Japan as a strategic hub for global expansion and a dual-track strategy developing both traditional and emerging biologics, Mycenax is well-positioned to enhance its global service capacity and realize its vision of becoming a world-class Bio-CDMO.

About Mycenax

Mycenax is a pioneer in biopharmaceutical CDMO in Taiwan, offering a fully integrated value chain including cell line development, manufacturing processes, analytical methods, and formulation development.

Mycenax operates two GMP-compliant facilities that provide comprehensive manufacturing solutions from drug substance (DS) to drug product (DP) with passed inspections by global regulatory authorities, including the EMA (Europe), PMDA (Japan), and Health Canada. To enhance its global CDMO services, Mycenax partnered with KriSan Biotech in 2022, a provider of antibody, linkers, payloads, and ADC GMP production capabilities. Mycenax and Krisan Biotech are committed to continuously advancing their expertise in site-specific binding, multi-arm structures, dual payloads, and novel functional linkers to meet the growing demand for next-generation ADCs.

Press Contact:

Liru Yeh

Email: liru.yeh@mycenax.com